...
首页> 外文期刊>The journal of clinical investigation >Concerns about the interpretation of subgroup analysis
【24h】

Concerns about the interpretation of subgroup analysis

机译:对亚组分析解释的担忧

获取原文
   

获取外文期刊封面封底 >>

       

摘要

To the Editor: We read with interest the article by Li et al. on the association between the use of ACE inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) and in-hospital mortality among patients with COVID-19 ( 1 ). The authors concluded that the use of ARBs was associated with a significant reduction in in-hospital mortality among African American patients but not non–African American patients. However, we believe this conclusion is not per statistical principles and that it potentially misguides readers. As noted by Altman and Bland ( 2 ), statistical analysis should be targeted to the clinical question: is the association between ARB use and in-hospital mortality different between African American and non–African American patients? To answer this question, one should directly compare the estimates (interaction test; ref. 2 ) performed and reported by the authors. Here we argue that the authors did not accurately interpret this analysis. The authors showed an odds ratio (OR) of 0.196 (95% confidence interval [CI] 0.074–0.516) in the African American population and an OR of 0.687 (95% CI 0.427–1.106) in the non–African American population. Accordingly, the interaction term was not significant (95% CI 0.185–1.292; P = 0.149; ref. 1 ). As the authors stated that “Statistical significance was defined as a 2-sided P value less than 0.05, unless otherwise stated,” the correct interpretation of this result would be that the association of ACE-I/ARB use and in-hospital mortality was not significantly different between these 2 populations ( 2 ). In contrast to this interpretation, the authors concluded that the association was only present in the African American population, which is not compatible with their analysis. The potential association between ACE-I/ARB use and COVID-19 in-hospital mortality is of great interest to the medical community. Further, the ability to provide reliable subgroup analyses is vital in clinical decision-making ( 3 ). Interaction analyses are essential to answer the clinically relevant question of whether a specific subgroup of patients can benefit more from an intervention than another group. However, we believe the correct interpretation of these results does not support the author’s conclusion.
机译:向编辑:我们利息读到Li等人的文章。关于ACE抑制剂(ACE-IS)和血管紧张素受体阻滞剂(ARB)的使用与Covid-19(1)患者的住院死亡率之间的关联。作者得出结论,ARB的使用与非洲裔美国患者中的住院内死亡率显着降低有关,而不是非洲裔美国患者。但是,我们认为这一结论不是统计原则,它可能是误导读者。正如Altman和Bland(2)所指出的那样,统计分析应针对临床问题:ARB之间的使用和非洲裔美国非裔美国人患者之间的医院死亡率与医院死亡率不同吗?为了回答这个问题,应该直接比较作者执行和报告的估计数(互动测试; 2)。在这里,我们认为作者没有准确地解释这种分析。作者展示了非洲裔美国人口的非洲裔美国人口和0.687(95%)或0.687(95%CI 0.427-1.106)中的0.196(95%置信区间[CI] 0.074-0.516)。因此,相互作用项不显着(95%CI 0.185-1.292; P = 0.149; REF。1)。由于作者表示“统计显着性被定义为小于0.05的双面P值,除非另有说明,”这种结果的正确解释将是ACE-I / ARB使用的协会和医院死亡率是这两个人群(2)之间没有显着差异。与这种解释相比,作者得出结论,该协会仅在非洲裔美国人口中存在,这与其分析不兼容。 ACE-I / ARB使用与Covid-19在医院的潜在关联对医学界非常感兴趣。此外,提供可靠的亚组分析的能力对于临床决策(3)至关重要。相互作用分析对于回答特定患者特定亚组可以从干预的临床相关问题提供比另一组的临床相关问题。但是,我们认为对这些结果的正确解释不支持作者的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号